SEARCH

SEARCH BY CITATION

References

  • 1
    The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema. ISAAC Lancet 1998; 351:122532.
  • 2
    Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998; 53:142.
  • 3
    Bousquet J, Calvayrac P, Guerin B. Immunotherapy with a standardized Dermatphagoides pteronyssinus extract. I. In vivo and in vitro parameters after a short course of treatment. J Allergy Clin Immunol 1985; 76:73444.
  • 4
    Lockey RF, Benedict LM, Turkeltaub PC, Bukantz SC. Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol 1987; 79:66077.
  • 5
    Ferrer M, Burches E, Pelaez A et al. Double-blind, placebo-controlled study of immunotherpay with Parietaria judaica: clinical efficacy and tolerance. J Invest Allergol Clin Immunol 2005; 15:28392.
  • 6
    Ariano R, Kroon AM, Augeri G, Canonica GW, Passalacqua G. Long-term treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial. Allergy 1999; 54:3139.
  • 7
    Tari MG, Mancino M, Ghezzi E, Frank E, Cromwell O. Immunotherapy with an alum-adsorbed Parietaria-pollen allergoid: a 2-year, double-blind, placebo-controlled study. Allergy 1997; 52:6574.
  • 8
    Bousquet J, Hejjaoui A, Soussana M, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid. J Allergy Clin Immunol 1990; 85:4907.
  • 9
    Pastorello EA, Pravettoni V, Incorvaia C et al. Clinical and immunological effects of immunotherapy with alum-absorbed grass allergoid in grass-pollen-induced hay fever. Allergy 1992; 47:28190.
  • 10
    Hendrix SG, Patterson R, Zeiss CR et al. A multi-institutional trial of polymerized whole ragweed for immunotherapy of ragweed allergy. J Allergy Clin Immunol 1980; 66:48694.
  • 11
    Grammer LC, Shaughnessy MA, Patterson R. Standardization of modified allergens using polymerized ragweed as a model system. Clin Rev Allergy 1987; 5:10716.
  • 12
    Colombo P, Duro G, Costa MA et al. An update on allergens. Parietaria pollen allergens. Allergy 1998; 53:91721.
  • 13
    Stumvoll S, Westritschnig K, Lidholm J et al. Identification of cross-reactive and genuine Parietaria judaica pollen allergens. J Allergy Clin Immunol 2003; 111:9749.
  • 14
    Asturias JA, Ibarrola I, Eseverri JL, Arilla MC, Gónzalez-Rioja R, Martínez A. PCR-based cloning and immunological characterization of Parietaria judaica pollen profilin. J Invest Allergol Clin Immunol 2004; 14:438.
  • 15
    Mothes N, Valenta R, Spitzauer S. Allergy testing: the role of recombinant allergens. Clin Chem Laboratory Med 2006; 44:12532.
  • 16
    Ibarrola I, Sanz ML, Gamboa P et al. Biological characterization of glutaraldehyde-modified Parietaria judaica pollen extracts. Clin Exp Allergy 2004; 34:3039.
  • 17
    Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:24854.
  • 18
    González-Rioja R, Ibarrola I, Arilla MC, Martínez A, Asturias JA. Expression and purification of the recombinant allergens Par j 1 and Par j 2. Abstract Book of XXIII EAACI Congress 2004; 1812 [Abstract].
  • 19
    Ceska M, Eriksson R, Varga J. Radioimmunosorbent assay of allergens. J Allergy Clin Immunol 1972; 49:19.
  • 20
    EAACI. Position paper: immunotherapy. (EAACI) The European academy ñof allergology and clinical immunology. Allergy 1993; 48:73.
  • 21
    Anderson MC, Baer H. RAST-inhibition and isoelectric focusing. Arb Paul Ehrlich Inst 1983; 79:11317.
  • 22
    Gewurz A, Grammer LC, Shaughnessy MA, Patterson R. Soluble copolymer of wasp venom with human albumin for venom immunotherapy. J Allergy Clin Immunol 1986; 77:5203.
  • 23
    Casanovas M, Sastre J, Lluch M et al. Double-blind study of tolerability and antibody production of unmodified and chemically modified allergen vaccines of Phleum pratense. Clin Exp Allergy 2005; 35:137783.
  • 24
    Negro JM, López JD, Pagán JA, Funes E, Pascual A, García Selles J. Clinical efficacy and safety of a depigmented and glutaraldehyde polymerized therapeutic vaccine of Parietaria judaica. Allergol Immunopathol 2003; 31:639.
  • 25
    Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed si-grass pollen allergoid. Allergy 2005; 60:8017.
  • 26
    Casanovas M, Fernández-Caldas E, Alamar R, Basomba A. Comparative study of tolerance between unmodified and high doses of chemically modified allergen vaccines of Dermatophagoides pteronyssinus. Int Arch Allergy Immunol 2005; 137:2118.
  • 27
    Haddad ZH, Marsh DG, Campbell DH. Studies on ‘allergoids’ prepared from naturally occurring allergens. II. Evaluation of allergenicity and assay of antigenicity of formalinized mixed grass pollen extracts. J Allergy Clin Immunol 1972; 49:197209.
  • 28
    Kahlert H, Stüwe H-T, Cromwell O, Fiebig H. Reactivity of T cells with grass pollen allergen extract and allergoid. Int Arch Allergy Immunol 1999; 120:14657.
  • 29
    Flicker S, Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol 2003; 132:1324.